The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

Researchers said the new findings add to a small but growing body of evidence that microplastic pollution represents an emerging health threat. In terms of its relationship with stroke risk, for ...

The HERZCHECK trial demonstrates the feasibility and diagnostic value of a mobile, CMR-based screening strategy for detecting asymptomatic stage B HF in rural, high-risk populations. Participants in ...

AZD0780, a novel, once-daily oral molecule inhibitor, had a robust, dose-dependent effect in lowering LDL-C and a favorable safety profile in patients with hypercholesterolemia already on background ...

The ZENITH trial demonstrated that among high-risk adults with PAH on maximum tolerated dose of background therapy, treatment with sotatercept resulted in a lower risk of all-cause death, lung ...

Angiopoietin-like 3 (ANGPTL-3) inhibition with the human monoclonal antibody, SHR-1918, reduces serum LDL-C by 22% to 30%, as well as triglyceride (TG) levels by 52% to 63%, in patients at moderate or ...

Coronary atherosclerotic phenotypes, including total plaque volume (TPV), noncalcified plaque (NCP), calcified plaque (CP) and percentage atheroma volume (PAV), assessed by artificial ...

Christopher M. Kramer, MD, FACC, received his medical degree from the University of California, San Francisco School of Medicine, and completed his residency and chief residency in internal medicine, ...

"Refocusing and reframing the definition and discussion of coronary artery disease (CAD) from late-stage ischemia and acute coronary events to early detection of coronary artery atheroma and ...

Sotatercept, a first-in-class novel activin-signaling inhibitor, led to a 76% lower risk of a composite of death from any cause, lung transplantation or hospitalization for worsening pulmonary ...

Among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD), the baseline estimated glomerular filtration rate (eGFR) did not impact the ...

The ALIGN-AR trial contributes to the literature by demonstrating high technical success, a reassuring safety profile, and favorable clinical outcomes in high-risk patients with aortic regurgitation ...